Effects of nicotine product claims on perceptions and behavior
Official title: Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior
Run by Ohio State University Comprehensive Cancer Center · NCT06192316 · Data updated 2026-11-12
This study tests how different claims about nicotine in oral nicotine pouches affect how young adults and tobacco users think and act towards these products.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | September 14, 2028 |
| Study ends | September 14, 2028 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT06192316 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include young adults aged 18-24 who are susceptible non-users of tobacco and adults aged 18-65 who are current tobacco users.
✕Probably not a fit
Patients who are not susceptible to nicotine use or are outside the age range of 18-65 will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates how different claims about nicotine concentration and sources affect young adults and adult tobacco users' perceptions and behaviors towards oral nicotine pouches (ONPs). Participants will engage in a laboratory setting where they will view randomized images of ONP packaging and complete various assessments, including psychophysiological tests and questionnaires. The primary objectives are to understand the impact of these claims on engagement with the product and self-reported behavioral intentions regarding ONPs.
Why it matters
Potential benefit: If successful, this study could provide insights into how nicotine product marketing influences behavior, potentially informing public health strategies for tobacco control.
How similar studies have gone: Other studies have explored the effects of tobacco product marketing on behavior, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Young adult susceptible non-users aged 18-24 who have never used ONPs and have never used but are susceptible to using either:
* combustible tobacco only (cigarettes, cigars, waterpipe)
* non-combustible tobacco only (ST, ECs, heated tobacco products)
* or both combustible and non-combustible tobacco (i.e., dual susceptibility)
* Adult tobacco users aged 18-65 who have never used ONPs OR have used ONPs \>3 months ago and 10 times or less in their lifetime. All adult tobacco users must also be:
* exclusive combustible tobacco users
* exclusive non-combustible tobacco users
* dual users
* For adult tobacco users, we will define current use as use of combustible and/or non-combustible tobacco every day or some days for 6 months or longer
* Willing and able to complete an in-person lab visit.
Exclusion Criteria:
* Age \< 18 or \> 65
* Are not susceptible non-users or current tobacco users
* Are unwilling or unable to complete and in person lab visit.
* Have used ONPs within the past 3 months
* Have used ONPs more than 10 times in their lifetime
Where it's running
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: Darren Mays, MPH, PhD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tracking risk awareness and improving knowledge about alcohol-related breast cancer in young adult women
This project will test whether co-created digital messages can reduce drinking and increase young women's awareness that alcohol raises breast cancer risk.
-
Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager
This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.
-
Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer
This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
DCE-MRI to help plan surgery for borderline resectable pancreatic cancer
This trial tests whether adding DCE-MRI imaging to standard care can better gauge how pancreatic tumors respond to treatment in patients whose cancer might be removable by surgery.
-
Navigation program to boost survivorship support participation for non-metastatic breast cancer survivors
This program tests whether a patient navigation service helps non-metastatic breast cancer survivors use survivorship support services more often.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.